Xenograft Animal Service: Immunocompromised NOD/SCID Mice
Xenografting is an established technique wherein tumor tissue from one species is transplanted into individuals of a different species. Xenografts of human tumor tissue into immunocompromised mice can provide a more accurate model of tumor growth and activity of administered drugs than in vitro studies. Altogen Labs offers in vivo xenograft services to conduct drug development for oncology, inflammation, diabetes, infectious diseases, obesity, immunology and pain research. Xenograft is a powerful research tool in oncology, playing a major role in development of new anti-cancer medicines.
Xenograft in vivo services are performed to measure the activity of compounds based on the rate of engrafted tumor growth. The xenotransplantation process involves administration of tumorigenic cell lines via subcutaneous injection. Alternative xenotransplantation approaches that can be performed by Altogen Labs include orthotopic, intramuscular, intravenous, intratracheal, or intraperitoneal administration.
Altogen Labs offers assistance in choosing the best model suitable for clients experimental goals. Animal handling and maintenance at our facility is IACUC-regulated and GLP-compliant. We provide detailed experiment procedures, health reports and experimental data. Additional experimental services include tissue collection, histology, RNA isolation and gene expression analysis.
Download Altogen Labs In Vivo Xenograft Services PowerPoint Presentation: [Download ]
BASIC STUDY DESIGN
• 8- to 12-week-old female BALB/c athymic (nude) mice (Nu/Nu)
• 9-14 week old NOD/SCID immunocompromised mice (SCID)
Xenografting is accomplished by subcutaneous injection of tumor cell line cells (typically 1,000,000 cells per animal, single flank injection in 50% matrigel). Tumors are established in a group of mice (usually 5-10 animals per experimental group) and tumor growth is detectable within 4-7 days post implantation.
Clients select a cell line of interest (must be tumorigenic cell line) and assign the number of experimental groups and the size of each group. The dosing of compounds is initiated when the mean tumor size reaches 50-100 mm3. Clients are expected to provide dose/group assignment instructions for each group.
Administration options include the dosing route (intratumoral, intramuscular, oral, intravenous, intratracheal, subcutaneous, or intraperitoneal), dosing frequency (for example, once or twice a day), and dosing duration. If the client elects to include the cyclophosphamide positive control group, cyclophosphamide (50 mg/kg) will be administered by intramuscular injection daily for the duration of the study.
We perform daily analysis with cage-side observations, and measure body weight and tumor volume every 2 days. Tumor volume (mm3) is calculated using the “(W x W x L) / 2” formula, where W is tumor width and L is tumor length.
Altogen Labs offers multiple xenograft tumor models, including A549, DU-145, PC-3, U87MG, MDA-MB, PANC1, Caki-1, Caki-2, SKMEL, A431, LnCAP, FaDu, HeLa, SKOV-3, SW-480, and many other cell lines (see Table 1 below for most commonly used cell lines). Following acclimatization, mice are grouped according to body weight. Human cancer cell lines are prepared in matrigel and grafted subcutaneously into the flank area. Mice are checked daily for clinical signs and tumor appearance.
When tumors begin to appear, animals are grouped based on tumor volume. Mice are dosed once or twice a day for 28 days via the chosen route of administration (choice of oral, intratumoral, intraperitoneal, intratracheal, intramuscular, or subcutaneous). Other available services include collection of blood sera at termination, and preservation of tumors and other major tissues. Optional positive control group utilizing cyclophosphamide, cyclophosphamide (50 mg/kg) can be administered by intramuscular injection daily for the duration of the study.
Table 1. Altogen Labs validated Xenograft animal models.
Select specific cell line below to see xenograft model data:
|Tumor Type:||Altogen Labs in-house validated cancer xenograft models:|
|Brain||U87 MG, LN229, U87-Luc, SK-N-AS, SF268, SF295, SF539, SNB19, UG-251MG|
|Breast Cancer||4T1, BT474, MCF-7, MDA-MB-231, MDA-MB-468, HS578T, MDA-MB-453, MDA-MB-157, KPL-4, T47D|
|Colon||COLO205, CT-26, MC38, SW-620, LS-174T, WiDr, SW480, HT-29, L0Vo, HCT116, DLD-1, KM-12|
|Gastric||NCI-N87, HS746T, AGS, MKN-45, SNU-16|
|Hepatocellular / Liver||Hep3B, HepG2, SK-HEP1, SMMC-7721, H22, Hepa1-6|
|Leukemia/Lymphoma||HL-60, K-562, MOLM13, MV4-11, DOHH2, Karpas-299, Ramos, A20, Raji, EL-4|
|Lung||A549, H460, H226, NCI-H1975, SAS, Calu-3, Calu-6, H1155|
|Melanoma||A2058, A375, B16|
|Other||A431, FaDu, HeLa|
|Pancreas||AsPC-1, MIAPaCa-2, BxPc-3|
|Prostate||DU-145, LNCaP, PC-3|
|Renal / Kidney||786O, Renca|
Contact us with the details of your project at firstname.lastname@example.org or call Altogen Labs at 512-433-6177. We will be happy to send an immediate price quotation and project timeline estimate. Please note that experimental details will help us to provide an accurate quote.
Pharmacology and Toxicology Testing: IC50 for Tumor Cell Lines | Xenograft Animal Service: Immunocompromised NOD/SCID Mice | Therapeutic RNAi Development: Targeted siRNA, qPCR Assays | Liposome Encapsulation Services: siRNA, miRNA, DNA, Proteins | ELISA and Cell-Based Assay Development (Cell Cycle, Viability) | Apoptosis Assay: Caspase-3 and Caspase-7 Cell Line Screen | RNAi Consulting: Technology Development and Evaluation